Gosset Year Founded
2011
Ownership
Public
Employees
~500
Therapeutic Areas
Stage
Phase 3
Modalities
ADC Therapeutics General Information
ADC Therapeutics has reported positive initial data from the LOTIS-7 clinical trial evaluating ZYNLONTA in combination with a bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma. The company has also completed enrollment for a Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab.
Contact Information
Drug Pipeline
loncastuximab tesirine
Phase 3Key Partnerships
Roche (rituximab)
ADC Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Later Stage VC | May 6, 2024 | $105.0M | Completed | Phase 3 |
To view ADC Therapeutics's complete valuation and funding history, request access »
ADC Therapeutics Licensing Deals
| Asset | Licensee | Date | Therapeutic Area |
|---|---|---|---|
| zynlonta | HCR | Aug 25, 2021 | Oncology |
| ZYNLONTA | Healthcare Royalty Management | Aug 25, 2021 | Oncology |
You're viewing 2 of 6 licensing deals. Get the full list »
ADC Therapeutics Investors
originally spun out from Spirogen Ltd.; likely includes venture capital/private equity backers at founding.
Investor Type: Venture Capital
Holding: Minority